Myeloma

ORR of 80% at recommended dose of talquetamab, teclistamab but with high rates of grade 3/4 AEs

Study finds TCL1A levels higher in responders, offering insights for improving outcomes

Greater area deprivation linked to worse progression-free and overall survival

Experts weigh the role of MRD in personalizing treatment but caution against premature changes

High rates of durable response in difficult-to-treat disease, with good tolerability

Study paves the way for quadruple therapy in patients not eligible for a stem cell transplant

Reduced toxicity and improved convenience position new treatments for broader use

Rapid evaluation and novel therapies may improve outcomes for these patients

Experts at ASH debate quadruplet therapy, dexamethasone modulation, and novel approaches

Study links strong relationships to better physical and emotional outcomes in myeloma care

Longer gaps between anti-BCMA agents associated with improved response rates, study finds

Phase III trial sparks discussion on defining and managing high-risk smoldering myeloma

DREAMM-7 findings help pave the way for Blenrep's return

Higher response rate, PFS, OS with cilta-cel, but ide-cel had lower rate of severe toxicity